1. HOME
  2. HOME
  3. ABOUT US
  4. COMPANY
 

Company overview

Company RevolKa Ltd.
​Headquarter 2-26-9 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
Establish Date April 7th, 2021
Capital 175 million yen (As of January 31, 2024)
Management President and CEO             Norio Hamamatsu, Ph.D.
Board Director and CSO   Mitsuo Umetsu, Ph.D.
Board Director                 Ayumi Iwase
Outside Board Director   Tetsuro Higuchi
Corporate Auditor            Naoya Onaka
Adviser Technical Advisor                Hikaru Nakazawa, Ph.D.
Scientific Advisor                Kouji Tsuda, Ph.D.
Scientific Advisor                Hahumi Nishi, Ph.D.
Strategy Advisor                 Kentaro Yoshimatsu, Ph.D.
Business Category Development of highly functional proteins using AI
Number of Employees 16(including officers and temporary employees)

Origin of company name

A fetus growing up

"RevolKa" is derived from the Latin word for evolution (evolutio) and the Ainu word for raise (reska). Our company logo takes inspiration from the developing fetus and represents that to raise (R of reska) nurtures evolution (e of evolution) with care.​

We have evolved the protein selected by life as a functional molecule into a frontier that could not be reached in nature by using evolutionary molecular engineering that mimics evolution in vitro using artificial intelligence technology as a guide. We will grow it as a functional molecule required by various fields focusing on medicine.

History

April, 2021 Established RevolKa Ltd. in Chuo-ku, Tokyo as a venture from Tohoku University
June, 2021 Concluded a joint research agreement with Tohoku University
June, 2021 Completed funding in the first seed round
January, 2022 Opened Sendai Lab in Aoba Ward, Sendai City
January, 2022 Completed funding in the second seed round
March, 2022 Concluded a joint research agreement with Sumitomo Dainippon Pharma Co., Ltd. (now Sumitomo Pharma Co., Ltd.)
April, 2022 Opened Tokyo Laboratory in Chuo-ku, Tokyo
May, 2022 Completed Series A round of funding
September, 2022 Opened US office in Cambridge, Massachusetts, USA
October, 2022 Concluded a joint research agreement with Tokyo Medical and Dental University
November, 2022 Relocated Tokyo Laboratory to Bunkyo-ku, Tokyo
July, 2023 Relocated Head office to Bunkyo-ku, Tokyo
September, 2023 Closed Tokyo Laboratory
January, 2024 Completed Series A extension round of funding

Co-founder

SHIRO KATAOKA

SHIRO KATAOKA

MITSUO UMETSU

MITSUO UMETSU

HIKARU NAKAZAWA

HIKARU NAKAZAWA

Locations

RevolKa head office

2-26-9 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

From the nearest station

About 5-minutes walk from Exit 2 of "Hongo 3cyoume Station" on the Tokyo Metro Marunouti Line

Sendai Lab

6-6-40-401・305・309 Aoba, Aramaki, Aoba-ku, Sendai 980-8579, Japan

From the nearest station

About 2-minutes walk from the North Exit of "Aobayama Station" on Sendai Subway Tozai Line
About 2-minute walk from the south Exit of "Aobayama Station" on Sendai Subway Tozai Line

RevolKa U.S. Office

One Broadway, Cambridge, MA 02142, USA

TECHNOLOGY

Click here for information on Revolca Ltd.'s technology.

Read more

RECRUIT

Click here for information on current vacancies.

Read more

CONTACT

Please contact from here.